KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity (2018 - 2022)

Historic Debt to Equity for TherapeuticsMD (TXMD) over the last 8 years, with Q3 2022 value amounting to -$1.94.

  • TherapeuticsMD's Debt to Equity rose 4043.72% to -$1.94 in Q3 2022 from the same period last year, while for Sep 2022 it was -$1.94, marking a year-over-year increase of 4043.72%. This contributed to the annual value of -$2.01 for FY2021, which is 490.72% down from last year.
  • According to the latest figures from Q3 2022, TherapeuticsMD's Debt to Equity is -$1.94, which was up 4043.72% from -$3.48 recorded in Q2 2022.
  • TherapeuticsMD's Debt to Equity's 5-year high stood at $23.98 during Q2 2019, with a 5-year trough of -$19.41 in Q1 2021.
  • Over the past 5 years, TherapeuticsMD's median Debt to Equity value was -$1.94 (recorded in 2022), while the average stood at -$0.31.
  • The largest annual percentage gain for TherapeuticsMD's Debt to Equity in the last 5 years was 271133.7% (2019), contrasted with its biggest fall of 177729.77% (2019).
  • Quarter analysis of 5 years shows TherapeuticsMD's Debt to Equity stood at $0.75 in 2018, then skyrocketed by 2711.34% to $21.15 in 2019, then crashed by 109.06% to -$1.92 in 2020, then dropped by 4.91% to -$2.01 in 2021, then increased by 3.57% to -$1.94 in 2022.
  • Its last three reported values are -$1.94 in Q3 2022, -$3.48 for Q2 2022, and -$1.44 during Q1 2022.